Ardelyx (FRA:41X) Short-Term Capital Lease Obligation : €1.2 Mil (As of Mar. 2025)

View and export this data going back to 2014. Start your Free Trial

What is Ardelyx Short-Term Capital Lease Obligation?

Ardelyx's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was €1.2 Mil.

Ardelyx's quarterly Short-Term Capital Lease Obligation declined from Sep. 2024 (€2.3 Mil) to Dec. 2024 (€1.5 Mil) and declined from Dec. 2024 (€1.5 Mil) to Mar. 2025 (€1.2 Mil).

Ardelyx's annual Short-Term Capital Lease Obligation increased from Dec. 2022 (€3.7 Mil) to Dec. 2023 (€4.1 Mil) but then declined from Dec. 2023 (€4.1 Mil) to Dec. 2024 (€1.5 Mil).

Ardelyx Short-Term Capital Lease Obligation Historical Data

The historical data trend for Ardelyx's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ardelyx Short-Term Capital Lease Obligation Chart

Ardelyx Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

1.74

3.09

3.68

4.07

1.49

Ardelyx Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															3.97	3.30	2.31	1.49	1.20

Ardelyx Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Ardelyx Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Ardelyx's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Ardelyx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ardelyx Inc (FRA:41X) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ARDX:USA 41X:Germany

Address

400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451

Website

https://www.ardelyx.com

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Ardelyx Headlines

No Headlines